Literature DB >> 23154260

Structural vaccinology starts to deliver.

Philip R Dormitzer1, Guido Grandi, Rino Rappuoli.   

Abstract

Following the impact of the genomics revolution on vaccine research and the development of reverse vaccinology, it was predicted that another new approach, structure-based antigen design, would become a driving force for vaccine innovation. Now, 5 years on, there are several examples of how structure-based design, or structural vaccinology, can deliver new vaccine antigens that were not possible before. Here, we discuss some of these examples and the contribution of structural vaccinology to our understanding of the protective epitopes of important bacterial and viral pathogens.

Mesh:

Substances:

Year:  2012        PMID: 23154260     DOI: 10.1038/nrmicro2893

Source DB:  PubMed          Journal:  Nat Rev Microbiol        ISSN: 1740-1526            Impact factor:   60.633


  53 in total

1.  Electron microscopy of the human respiratory syncytial virus fusion protein and complexes that it forms with monoclonal antibodies.

Authors:  L J Calder; L González-Reyes; B García-Barreno; S A Wharton; J J Skehel; D C Wiley; J A Melero
Journal:  Virology       Date:  2000-05-25       Impact factor: 3.616

2.  Structure-based approach to rationally design a chimeric protein for an effective vaccine against Group B Streptococcus infections.

Authors:  Annalisa Nuccitelli; Roberta Cozzi; Louise J Gourlay; Danilo Donnarumma; Francesca Necchi; Nathalie Norais; John L Telford; Rino Rappuoli; Martino Bolognesi; Domenico Maione; Guido Grandi; C Daniela Rinaudo
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-18       Impact factor: 11.205

3.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

Authors:  H W Kim; J G Canchola; C D Brandt; G Pyles; R M Chanock; K Jensen; R H Parrott
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

4.  A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination.

Authors:  Peter T Beernink; Jutamas Shaughnessy; Emily M Braga; Qin Liu; Peter A Rice; Sanjay Ram; Dan M Granoff
Journal:  J Immunol       Date:  2011-02-16       Impact factor: 5.422

5.  Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention.

Authors:  Margarita Magro; Vicente Mas; Keith Chappell; Mónica Vázquez; Olga Cano; Daniel Luque; María C Terrón; José A Melero; Concepción Palomo
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-08       Impact factor: 11.205

6.  A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins.

Authors:  Davide Corti; Jarrod Voss; Steven J Gamblin; Giosiana Codoni; Annalisa Macagno; David Jarrossay; Sebastien G Vachieri; Debora Pinna; Andrea Minola; Fabrizia Vanzetta; Chiara Silacci; Blanca M Fernandez-Rodriguez; Gloria Agatic; Siro Bianchi; Isabella Giacchetto-Sasselli; Lesley Calder; Federica Sallusto; Patrick Collins; Lesley F Haire; Nigel Temperton; Johannes P M Langedijk; John J Skehel; Antonio Lanzavecchia
Journal:  Science       Date:  2011-07-28       Impact factor: 47.728

7.  Vaccine potential of the Neisseria meningitidis 2086 lipoprotein.

Authors:  Leah D Fletcher; Liesel Bernfield; Vicki Barniak; John E Farley; Alan Howell; Melissa Knauf; Peggy Ooi; Robert P Smith; Paige Weise; Mike Wetherell; Xiaoling Xie; Robert Zagursky; Ying Zhang; Gary W Zlotnick
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

Review 8.  Vaccines for the twenty-first century society.

Authors:  Rino Rappuoli; Christian W Mandl; Steven Black; Ennio De Gregorio
Journal:  Nat Rev Immunol       Date:  2011-11-04       Impact factor: 53.106

9.  Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates.

Authors:  Muriel C Schneider; Beverly E Prosser; Joseph J E Caesar; Elisabeth Kugelberg; Su Li; Qian Zhang; Sadik Quoraishi; Janet E Lovett; Janet E Deane; Robert B Sim; Pietro Roversi; Steven Johnson; Christoph M Tang; Susan M Lea
Journal:  Nature       Date:  2009-02-18       Impact factor: 49.962

10.  Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells.

Authors:  Mark Throsby; Edward van den Brink; Mandy Jongeneelen; Leo L M Poon; Philippe Alard; Lisette Cornelissen; Arjen Bakker; Freek Cox; Els van Deventer; Yi Guan; Jindrich Cinatl; Jan ter Meulen; Ignace Lasters; Rita Carsetti; Malik Peiris; John de Kruif; Jaap Goudsmit
Journal:  PLoS One       Date:  2008-12-16       Impact factor: 3.240

View more
  59 in total

1.  Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus.

Authors:  Jason S McLellan; Man Chen; M Gordon Joyce; Mallika Sastry; Guillaume B E Stewart-Jones; Yongping Yang; Baoshan Zhang; Lei Chen; Sanjay Srivatsan; Anqi Zheng; Tongqing Zhou; Kevin W Graepel; Azad Kumar; Syed Moin; Jeffrey C Boyington; Gwo-Yu Chuang; Cinque Soto; Ulrich Baxa; Arjen Q Bakker; Hergen Spits; Tim Beaumont; Zizheng Zheng; Ningshao Xia; Sung-Youl Ko; John-Paul Todd; Srinivas Rao; Barney S Graham; Peter D Kwong
Journal:  Science       Date:  2013-11-01       Impact factor: 47.728

Review 2.  Advances in structure-based vaccine design.

Authors:  Daniel W Kulp; William R Schief
Journal:  Curr Opin Virol       Date:  2013-06-25       Impact factor: 7.090

3.  Structure-based Epitope Mapping of Mycobacterium tuberculosis Secretary Antigen MTC28.

Authors:  Prasun Kundu; Rupam Biswas; Somnath Mukherjee; Linda Reinhard; Anirudha Dutta; Jochen Mueller-Dieckmann; Manfred S Weiss; Nishit Kumar Pal; Amit Kumar Das
Journal:  J Biol Chem       Date:  2016-05-04       Impact factor: 5.157

4.  Coimmunization with Two Enterotoxigenic Escherichia coli (ETEC) Fimbrial Multiepitope Fusion Antigens Induces the Production of Neutralizing Antibodies against Five ETEC Fimbriae (F4, F5, F6, F18, and F41).

Authors:  Qiangde Duan; Wenwen Wu; Shengmei Pang; Zhiming Pan; Weiping Zhang; Guoqiang Zhu
Journal:  Appl Environ Microbiol       Date:  2020-11-24       Impact factor: 4.792

Review 5.  Adjuvanted influenza vaccines.

Authors:  John S Tregoning; Ryan F Russell; Ekaterina Kinnear
Journal:  Hum Vaccin Immunother       Date:  2018-01-25       Impact factor: 3.452

6.  Novel Ricin Subunit Antigens With Enhanced Capacity to Elicit Toxin-Neutralizing Antibody Responses in Mice.

Authors:  Newton Wahome; Erin Sully; Christopher Singer; Justin C Thomas; Lei Hu; Sangeeta B Joshi; David B Volkin; Jianwen Fang; John Karanicolas; Donald J Jacobs; Nicholas J Mantis; C Russell Middaugh
Journal:  J Pharm Sci       Date:  2016-03-15       Impact factor: 3.534

7.  Structural conservation, variability, and immunogenicity of the T6 backbone pilin of serotype M6 Streptococcus pyogenes.

Authors:  Paul G Young; Nicole J Moreland; Jacelyn M Loh; Anita Bell; Polly Atatoa Carr; Thomas Proft; Edward N Baker
Journal:  Infect Immun       Date:  2014-04-28       Impact factor: 3.441

8.  Broadly neutralizing epitopes in the Plasmodium vivax vaccine candidate Duffy Binding Protein.

Authors:  Edwin Chen; Nichole D Salinas; Yining Huang; Francis Ntumngia; Manolo D Plasencia; Michael L Gross; John H Adams; Niraj Harish Tolia
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-18       Impact factor: 11.205

Review 9.  Vaccine design: emerging concepts and renewed optimism.

Authors:  Sebastian K Grimm; Margaret E Ackerman
Journal:  Curr Opin Biotechnol       Date:  2013-03-07       Impact factor: 9.740

10.  Successful completion of a semi-automated enzyme-free cloning method.

Authors:  Stefano Bonacci; Scilla Buccato; Domenico Maione; Roberto Petracca
Journal:  J Struct Funct Genomics       Date:  2016-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.